In the original version of figure 7 from the aforementioned article, the histological images labelled as from the Ter20–28 group in panels d, h and l, had been mistakenly taken from the Ter10–28 group.
The authors have supplied new images from the Ter20–28 group for panels d, h and l, and the new figure is reproduced below.
Terguride (Ter) reverses monocrotaline (MCT)-induced collagen deposition. Chronic daily treatment with terguride at a dose of 0.4 or 1.2 mg·kg−1 from day 0 to day 28 after MCT-injection reversed collagen deposition as detected by a–h) Sirius red staining and i–l) Masson trichrome staining. e–h) Polarisation light revealed a clear accumulation of total collagen fibres (yellow, red and green). m) Quantitative image analysis data. Terguride treatment groups comprised group Ter10–28 (0.4 mg·kg−1 b.i.d. from day 0 to day 28) and group Ter20–28 (1.2 mg·kg−1 b.i.d. from day 0–28). MCT0–28 represents the corresponding vehicle-treated control. Data are presented as mean±sem. n=4. Scale bars 50 μm. *: p<0.05 versus control; #: p<0.05 versus MCT0–28.
- Copyright ©ERS 2021. For reproduction rights and permissions contact permissions{at}ersnet.org
